Multiple myeloma is a type of blood cancer that develops in plasma cells, a type of white blood cell found in the bone marrow. Because the disease can affect the blood, bones, kidneys, and immune system, diagnosis usually involves more than one laboratory or imaging procedure.
A multiple myeloma test may include blood tests, urine tests, bone marrow examination, imaging, and advanced genetic or molecular testing. Each test provides different information that can help doctors confirm the diagnosis, understand the characteristics of the disease, and plan appropriate care.
What Is Multiple Myeloma?
Plasma cells normally produce antibodies that help the body fight infections. In multiple myeloma, abnormal plasma cells grow and accumulate in the bone marrow.
These abnormal cells may produce an abnormal protein, often referred to as a monoclonal protein or M protein. The presence and amount of this protein can provide important information during diagnosis and monitoring.
Multiple myeloma can affect people differently. Some individuals may experience symptoms such as bone pain, fatigue, recurrent infections, anemia, or kidney problems, while others may initially have few or no noticeable symptoms.
Because these symptoms can also occur in other conditions, a proper diagnosis requires a detailed medical evaluation.
Why Is a Multiple Myeloma Test Important?
A multiple myeloma test helps healthcare professionals investigate whether abnormal plasma cells are present and determine how the condition is affecting the body.
Testing can also help distinguish multiple myeloma from related plasma cell disorders, including conditions that may require monitoring rather than immediate treatment.
Once multiple myeloma is diagnosed, additional testing can provide information about the disease's biological characteristics and help assess prognosis and treatment options.
Blood Tests Used in Multiple Myeloma Diagnosis
Blood tests are often an important part of the diagnostic process.
A complete blood count, or CBC, may be used to evaluate red blood cells, white blood cells, and platelets. Multiple myeloma can sometimes contribute to anemia or other blood abnormalities.
Doctors may also assess kidney function and calcium levels because the disease can affect these areas.
Specific blood tests can measure immunoglobulins and detect or quantify abnormal proteins produced by plasma cells.
Serum protein electrophoresis and immunofixation may help identify an M protein. A serum free light chain test can provide additional information about certain proteins produced by abnormal plasma cells.
No single blood test alone is usually sufficient to diagnose every case.
Urine Testing
A multiple myeloma test may also include urine analysis.
Some abnormal proteins or light chains may be present in the urine. Urine protein electrophoresis and related tests can help identify and measure these proteins when clinically appropriate.
Blood and urine findings are generally interpreted together with bone marrow and imaging results.
Bone Marrow Examination
A bone marrow aspiration and biopsy are important diagnostic procedures when multiple myeloma is suspected.
A sample of bone marrow is collected and examined to determine the number and characteristics of plasma cells.
The laboratory may also perform additional studies on these cells to better understand their biological features.
Bone marrow testing can play an important role in confirming the diagnosis and evaluating the extent of plasma cell involvement.
Imaging Tests for Multiple Myeloma
Imaging may be used to identify bone damage or other areas affected by the disease.
Depending on the clinical situation, doctors may use low-dose whole-body CT, MRI, PET-CT, or other imaging techniques.
The choice of imaging depends on the individual's symptoms, available clinical information, and the purpose of the evaluation.
Imaging findings can contribute to both diagnosis and ongoing disease assessment.
The Role of Genetic and Molecular Testing
Advanced genetic testing can provide additional information about multiple myeloma cells.
Tests such as fluorescence in situ hybridization, commonly known as FISH, may identify certain chromosomal abnormalities associated with the disease.
These findings can help doctors better understand the biological characteristics of the myeloma and may contribute to risk assessment and treatment planning.
Other molecular and genomic techniques may also be considered in specific clinical situations.
A multiple myeloma test involving genetic analysis is usually performed on the cancer cells rather than being a general inherited genetic test.
Understanding the Diagnostic Process
Doctors do not usually diagnose multiple myeloma based on one test alone.
The diagnosis may involve evaluating abnormal plasma cells in the bone marrow, the presence of monoclonal proteins, evidence of organ involvement, and other clinical findings.
The exact diagnostic criteria and interpretation should be determined by a hematologist or other qualified specialist.
Some individuals may have precursor conditions involving abnormal plasma cells or monoclonal proteins without meeting the criteria for active multiple myeloma.
This is why careful evaluation is essential.
Multiple Myeloma Testing and Disease Monitoring
Testing does not necessarily end after the initial diagnosis.
Blood and urine tests may be repeated to monitor abnormal protein levels and evaluate how the disease responds to treatment.
Bone marrow testing, imaging, and other laboratory studies may also be used at different stages of care.
The frequency and type of monitoring depend on the individual's condition and treatment plan.
The Importance of Early and Accurate Evaluation
Symptoms such as persistent bone pain, unexplained anemia, frequent infections, kidney problems, or unusual blood test results do not automatically mean a person has multiple myeloma.
However, when these findings are present, a doctor may recommend further investigation.
Early and accurate evaluation can help identify the cause of symptoms and ensure that appropriate care is provided.
Self-diagnosis based on symptoms or individual laboratory values should be avoided.
The Role of Advanced Diagnostics and MedGenome
Advances in genomics and molecular diagnostics are helping healthcare professionals understand the genetic characteristics of different cancers.
MedGenome works in the field of genomics and advanced diagnostics, supporting testing approaches that can provide molecular information relevant to cancer and other diseases.
In the context of multiple myeloma, advanced testing may help identify genetic and chromosomal changes in plasma cells that can contribute to disease classification and clinical decision-making.
The value of these tests depends on selecting the appropriate method and interpreting the results alongside pathology, blood tests, imaging, and the patient's overall clinical condition.
Limitations of Multiple Myeloma Tests
Every multiple myeloma test has a specific purpose and limitations.
A blood test may detect abnormal proteins but may not independently establish a diagnosis. Bone marrow findings require clinical interpretation, while imaging provides information about structural changes rather than the complete biological profile of the disease.
Genetic and molecular tests can provide additional information, but their results must be interpreted in the context of established clinical and laboratory findings.
A negative result from one test does not necessarily exclude every plasma cell disorder.
Why Specialist Interpretation Matters
Multiple myeloma is a complex condition, and its diagnosis and management require specialist evaluation.
A hematologist or oncologist can interpret laboratory reports, bone marrow findings, imaging results, and genetic data together.
This integrated approach is important because the same abnormal finding may have different clinical significance depending on the individual's overall condition.
Patients should discuss any suspected or confirmed diagnosis with their treating healthcare team before making decisions based on test results.
Final Thoughts
A multiple myeloma test can involve several diagnostic methods, including blood tests, urine analysis, bone marrow examination, imaging, and genetic or molecular testing.
Together, these investigations help healthcare professionals diagnose multiple myeloma, understand its characteristics, and monitor the condition over time.
Advanced diagnostic technologies, including molecular and genomic approaches associated with organizations such as MedGenome, are expanding the information available for evaluating blood cancers.
If multiple myeloma testing has been recommended, discussing the purpose of each test and the meaning of the results with a qualified hematologist or oncologist can help ensure the findings are understood in the right clinical context.
Disclaimer: This article is for informational and educational purposes only and should not replace professional medical advice, diagnosis, or treatment.
Top comments (0)